The Genetic Screening for Carrier Diseases ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively enable the delivery of carrier‑status diagnostics. Upstream, raw‑material and component suppliers provide reagents, extraction kits, and consumables required for nucleic‑acid analysis. Midstream, technology providers develop sequencing or microarray platforms and accompanying bio‑informatics algorithms, while system integrators assemble these components into turnkey laboratory solutions. Downstream, distributors and channel partners ensure regional availability, and service providers deliver validation, calibration, and maintenance services that sustain assay performance. End users—hospital genetics departments, reproductive‑health clinics, and reference laboratories—apply the tests to prospective parents. Value is captured through licensing of proprietary assays, consumable sales, and service contracts, while regulatory approval gates market entry.